Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * *   Welcome to STN International   * * * * * * * * * *

NEWS 1   Web Page for STN Seminar Schedule - N. America
NEWS 2   APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 3   APR 15 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 4   APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 5   APR 28 IMSRESEARCH reloaded with enhancements
NEWS 6   MAY 30 INPAFAMDB now available on STN for patent family
                 searching
NEWS 7   MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS 8   JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 9   JUN 06 KOREAPAT updated with 41,000 documents
NEWS 10   JUN 13 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
NEWS 11   JUN 19 CAS REGISTRY includes selected substances from
                 web-based collections
NEWS 12   JUN 25 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
NEWS 13   JUN 30 AEROSPACE enhanced with more than 1 million U.S.
                 patent records
NEWS 14   JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional
                 options to display authors and affiliated
                 organizations
NEWS 15   JUN 30 STN on the Web enhanced with new STN AnaVist
                 Assistant and BLAST plug-in
NEWS 16   JUN 30 STN AnaVist enhanced with database content from EPFULL
NEWS 17   JUL 28 CA/CAplus patent coverage enhanced
NEWS 18   JUL 28 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 19   JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 20   JUL 28 STN Viewer performance improved
NEWS 21   AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22   AUG 13 CA/CAplus enhanced with printed Chemical Abstracts
                 page images from 1967-1998
NEWS 23   AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 24   AUG 15 CAplus currency for Korean patents enhanced
NEWS 25   AUG 25 CA/CAplus, CASREACT, and IFI and USPAT databases
                 enhanced for more flexible patent number searching
NEWS 26   AUG 27 CAS definition of basic patents expanded to ensure
                 comprehensive access to substance and sequence
                 information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,

AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:06:08 ON 28 AUG 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 13:06:17 ON 28 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2
DICTIONARY FILE UPDATES: 26 AUG 2008 HIGHEST RN 1043895-06-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10516938.str

```
chain nodes :
1   2   3   4   5   6   7   8
ring nodes :
9   10   11   12   13   14   15   16   17   18   19   20   21   22   23   24   25
chain bonds :
1-2   2-3   3-4   4-5   4-6   6-7   6-8   8-12   9-15   19-24
ring bonds :
9-10   9-14   10-11   11-12   12-13   13-14   15-16   15-19   16-17   17-18   18-19   20-21
20-25   21-22   22-23   23-24   24-25
exact/norm bonds :
1-2   2-3   3-4   4-5   4-6   6-8   9-15   15-16   15-19   16-17
exact bonds :
6-7   8-12   17-18   18-19   19-24
normalized bonds :
9-10   9-14   10-11   11-12   12-13   13-14   20-21   20-25   21-22   22-23   23-24   24-25

isolated ring systems :
containing 9 : 15 : 20 :


Match level :
1:CLASS   2:CLASS   3:CLASS   4:CLASS   5:CLASS   6:CLASS   7:CLASS   8:CLASS   9:Atom
10:Atom
11:Atom   12:Atom   13:Atom   14:Atom   15:Atom   16:Atom   17:Atom   18:Atom   19:Atom
20:Atom   21:Atom
22:Atom   23:Atom   24:Atom   25:Atom




L1        STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1                STR
```

Structure attributes must be viewed using STN Express query preparation.


```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY      SESSION
FULL ESTIMATED COST                                         0.46         0.67

FILE 'CAPLUS' ENTERED AT 13:06:51 ON 28 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE COVERS 1907 - 28 Aug 2008  VOL 149 ISS 9
FILE LAST UPDATED: 27 Aug 2008  (20080827/ED)
```

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s L1 SSS full
   REGIstRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.
```

```
FULL SEARCH INITIATED 13:06:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      37 TO ITERATE

100.0% PROCESSED      37 ITERATIONS                          4 ANSWERS
SEARCH TIME: 00.00.01

L2          4 SEA SSS FUL L1



L3          3 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:      2004:370913  CAPLUS  Full-text
DOCUMENT NUMBER:       140:375166
TITLE:                 Preparation of nitric oxide releasing selective
                       cyclooxygenase-2 inhibitors
INVENTOR(S):           Wang, Zhaoyin; Young, Robert N.; Zamboni, Robert
PATENT ASSIGNEE(S):    Merck Frosst Canada & Co., Can.
SOURCE:                PCT Int. Appl., 57 pp.
                       CODEN: PIXXD2
DOCUMENT TYPE:         Patent
LANGUAGE:              English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ---------------     ----   --------    --------------------     --------
     WO 2004037798       A1     20040506    WO 2003-CA1605           20031021
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
           CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
           GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,
           LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
           PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
           TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
       RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
           KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
           FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
           BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2503063          A1     20040506    CA 2003-2503063          20031021
     AU 2003278039       A1     20040513    AU 2003-278039           20031021
     EP 1562914          A1     20050817    EP 2003-769122           20031021
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 2006058363       A1     20060316    US 2005-530214           20050404
PRIORITY APPLN. INFO.:                      US 2002-420292P    P  20021022
                                            WO 2003-CA1605     W  20031021
OTHER SOURCE(S):       MARPAT 140:375166
GI
```

I

II

AB   Novel compds. of formulas I and II [R = H, alkyl; L = bond, alkylidene,
      cycloalkylidene, aryl, etc.; X = O, S; Y = bond, S, O, (substituted) NH; m =
      0-4; n = 1-2; p = 1-4] are prepared, which are nitric oxide-releasing prodrugs
      useful in the treatment of cyclooxygenase-2 mediated diseases. The invention
      also encompasses certain pharmaceutical compns. and methods for treatment of
      cyclooxygenase-2 mediated diseases comprising the use of compds. I or II. The
      above compds. may be used as a combination therapy with low-dose aspirin to
      treat chronic cyclooxygenase-2 mediated diseases or conditions while
      simultaneously reducing the risk of thrombotic cardiovascular events.
IT   685107-04-4P
      RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
      (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
      (Uses)
         (preparation of nitrosated or nitrosylated prodrugs for cyclooxygenase-2
         inhibitors)
RN   685107-04-4 CAPLUS
CN   Acetamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
      yl]phenyl]sulfonyl]-2-(nitrooxy)- (CA INDEX NAME)

```
TITLE:                     Preparation of nitrooxy derivatives of
                           cyclooxygenase-2 inhibitors
INVENTOR(S):               Del Soldato, Piero; Santus, Giancarlo
PATENT ASSIGNEE(S):        Nicox S.A., Fr.
SOURCE:                    PCT Int. Appl., 27 pp.
                           CODEN: PIXXD2
DOCUMENT TYPE:             Patent
LANGUAGE:                  English
FAMILY ACC. NUM. COUNT:    1
PATENT INFORMATION:

    PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
    ---------------      ----   --------    -------------------      --------
    WO 2004000781        A2     20031231    WO 2003-EP6502           20030620
    WO 2004000781        A3     20041014
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
            PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR,
            TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    IT 2002MI1391        A1     20031229    IT 2002-MI1391           20020625
    CA 2491209           A1     20031231    CA 2003-2491209          20030620
    AU 2003245972        A1     20040106    AU 2003-245972           20030620
    EP 1517889           A2     20050330    EP 2003-738069           20030620
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1662490           A      20050831    CN 2003-814682           20030620
    JP 2005530836        T      20051013    JP 2004-514803           20030620
    NZ 537043            A      20060929    NZ 2003-537043           20030620
    ZA 2004010060        A      20051020    ZA 2004-10060            20041213
    MX 2004PA12851       A      20050224    MX 2004-PA12851          20041216
    NO 2005000346        A      20050208    NO 2005-346              20050121
    US 20060106082       A1     20060518    US 2005-516938           20050913
PRIORITY APPLN. INFO.:          IT 2002-MI1391          A    20020625
                                WO 2003-EP6502          W    20030620
OTHER SOURCE(S):        MARPAT 140:59410
AB  Disclosed are new compds. able to release COX-2 inhibitors and NO (no data)
    having formula M-T-YA-NO2 [wherein M-T = the residue of a COX-2 selective
    inhibitor (T = SO2NH, SO2NR, CO, O, S, NH, N(SO2R); R = C1-10 alkyl; the COX-2
    selective inhibitor, M-TH or M-TOH, has to meet test 2 mentioned in the
    description); YA = -(B)b0-(C)c0- [b0, c0 = 0,1, with the proviso that b0 and
    c0 cannot be simultaneously 0; B = TB-X2-TB1; TB = CO, X; X = O, S, NH, NR, R
    (defined above); TB = CO when T = SO2NH, SO2NR-O, S, NH, or N(SO2R), TB = X
    when T = CO; TB1 = CO or X (defined above); X2 = a divalent radical selected
    from the following compds. Q or Q1, etc. (n1, n2 = 0, 1; R2, R3 = H, Me; Y1 =
    CH2CH2, CH:CH(CH2)n2; n2 = 0, 1)]] for the treatment and/or prophylaxis of
    inflammatory disorders, pain, fever, cardiovascular disease, gastrointestinal
    disorders, tumors, Alzheimer's disease, or disorders resulting from elevated
    levels of COX-2.  These compds. including 5-niroxypentanoc acid, 4-
    nitrooxybutyric acid, and 4-nitrooxybutyramide, 2-nitroxymethylbenzoic acid
    ester derivs. mitigate or remove the known side-effects of COX-2 inhibitors.
    The inflammatory disorders are selected from the group consisting of, but not
    limited to, arthritis, rheumatoid arthritis, osteoarthritis, allergic
    rhinitis, sinusitis, chronic obstructive pulmonary diseases, dermatitis,
    psoriasis, cystic fibrosis, multiple sclerosis, vasculitis and organ
```

transplant rejection. The cardiovascular diseases are selected from the group
consisting of, but not limited to, atherosclerosis, restenosis, coronary
artery disease, angina, diabetes mellitus, diabetic nephropathy, diabetic
retinopathy, stroke and myocardial infarct. The gastrointestinal disorders
are selected from the group consisting of, but not limited to, inflammatory
intestinal disorders, Crohn's disease, gastritis, ulcerative colitis, peptic
ulcer, hemorrhagic ulcer, gastric hyperacidity, dyspepsia, gastroparesis,
Zollinger-Ellison's syndrome, bacterial infections, hypersecretory states
associated with systemic mastocytosis or basophilic leukemia and
hyperhystaminemia. The disorders resulting from elevated levels of COX-2 are
selected from the group consisting of, but not limited to, angiogenesis,
arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis,
neoplasia, ophthalmic diseases, pulmonary inflammations, central nervous
system disorders, allergic rhinitis, atherosclerosis, endothelial disorders,
organs and tissues preservation, inhibition and/or prevention of platelets
aggregation. Thus, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1-inden-
5-yl]-N-[4- (chloro)butyroyloxymethyl]methanesulfonamide. A solution of
chloromethyl (4-chloro)butyrate (1 g, 5.40 mmol) in anhydrous THF (5 mL) was
slowly added dropwise in a suspension of N-[6-[(2,4-difluorophenyl)thio]-2,3-
dihydro-1- oxo-1-inden-5-yl]methanesulfonamide sodium salt (2.04 g, 5.40 mmol)
in anhydrous THF (25 mL) and stirred at room temperature overnight to give,
after workup and silica gel chromatog., N-[6-[(2,4-difluorophenyl)thio]-2,3-
dihydro-1-oxo-1-inden-5-yl]-N-[4-(chloro)butyroyloxymethyl]methanesulfonam ide
(I). A solution of I (1 g, 1.98 mmol) in MeCN (20 mL) was added with AgNO3
(0.67 g, 3.96 mmol), heated at 80° for 15 h in the absence of light, filtered
to remove the silver salt, evaporated under vacuum, and purified by chromatog.
on a silica gel column to give with n-hexane/ethyl acetate 8/2 as eluent to
give 503 mg N-[6-[(2,4-difluorophenyl)thio]-2,3- dihydro-1-oxo-1-inden-5-yl]-
N-[4-(nitrooxy)butyroyloxymethyl]methanesulfon amide.

IT 586347-45-7P
    RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
    (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
    (Uses)
       (preparation of nitrooxy derivs. of cyclooxygenase-2 inhibitors for
       treatment and/or prophylaxis of inflammatory disorders, pain, fever,
       cardiovascular disease, gastrointestinal disorders, tumors, or
       Alzheimer's disease)
RN 586347-45-7 CAPLUS
CN Butanamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
    yl]phenyl]sulfonyl]-4-(nitrooxy)- (CA INDEX NAME)

II

AB   New pharmaceutical compds. of general formula F-(X)q (I) [q = 1-5, preferably 1; F is chosen among drugs such as δ-tocopherol, clidanac, diethylhomospermine, glucosamine, thymocartin, vofopitant, etc.; X is chosen among 4 groups M, T, V, and Y where M = ONO2, nitrate salt, nitrite ester, ONO, thoinitrite, SNO, etc., T = OR1-M, OR1OR1-M, SR1NR2R1-M, NR2R1-M, NR2R1SR1-M, etc., R1 = saturated or unsatd., linear or branched alkylene, having 1 to 21 carbon atoms or a saturated or unsatd., optionally heterosubstituted or branched cycloalkylene, having 3 to 7 carbon atoms or an optionally heterosubstituted arylene having 3 to 7 carbon atoms; R2 = H, saturated or unsatd., linear or branched 1-21 carbon atom alkyl, saturated or unsatd. optionally heterosubstituted or branched 3-7 carbon cycloalkyl, optionally heterosubstituted 3-7 carbon aryl; R1, R2 = OH, SH, F, Cl, Br, OPO3H2, CO2H, etc.; bond between F and T = carboxylic ester, carboxylic amide, glycoside, azo, thioester, sulfonic ester, etc.; V = Z-M2, OZ-M2, NR2Z-M2, R1Z-M2, OR1-M2, OR1Z-M2, M2 = M, R1-M, OR1-M, SR1-M, NR2R1-M; ZM2 = COCH2CH(M2)CH2N+Me3, COCH2CH2COM2, COCH(NHR2)CH2M2, etc.; Y = 4-COC6H4CH2ONO2, O(CH2)4ONO2, COCH(NH2)CH2ONO2, 3-OC6H4CH2ONO2, etc.] were prepared For example, α-tocopherol reacted with 4-HO2CC6H4CH2ONO2 to give the nitroxymethyl derivative II. The compds. of general formula I are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.

      RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
      (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
      (Uses)
         (preparation of nitrate prodrugs for treating or preventing inflammatory,
   ischemic, degenerative, and proliferative diseases)
RN   586347-45-7   CAPLUS
CN   Butanamide, N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
      yl]phenyl]sulfonyl]-4-(nitrooxy)-   (CA INDEX NAME)


RN   586347-46-8   CAPLUS
CN   Butanoic acid, 4-[[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
      yl]phenyl]sulfonyl]amino]-2,3-bis(nitrooxy)-4-oxo-   (CA INDEX NAME)

RN   586347-62-8   CAPLUS
CN   Butanamide, N-[[4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-
      pyrazol-1-yl]phenyl]sulfonyl]-4-(nitrooxy)-   (CA INDEX NAME)

```
REFERENCE COUNT:          19    THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file marpat
COST IN U.S. DOLLARS                             SINCE FILE      TOTAL
                                                    ENTRY      SESSION
FULL ESTIMATED COST                                 16.83       196.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)       SINCE FILE      TOTAL
                                                    ENTRY      SESSION
CA SUBSCRIBER PRICE                                 -2.40        -2.40

FILE 'MARPAT' ENTERED AT 13:07:32 ON 28 AUG 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 149 ISS 7 (20080822/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20080167493 10 JUL 2008
DE 102007009957 03 JUL 2008
EP     1939208 02 JUL 2008
JP   2008159496 10 JUL 2008
WO   2008086729 24 JUL 2008
GB      2444641 11 JUN 2008
FR      2910897 04 JUL 2008
RU      2330028 27 JUL 2008
CA      2615024 14 JUN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
have increased from 100,000 to 200,000 for both on-line and batch
searches.  For more information on MARPAT search limits, type HELP
SLIMITS at an arrow prompt.

=> s L1 SSS full
FULL SEARCH INITIATED 13:07:38 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -     131 TO ITERATE

100.0% PROCESSED      131 ITERATIONS                        1 ANSWERS
SEARCH TIME: 00.00.01

L4          1 SEA SSS FUL L1

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 13:07:47 ON 28 AUG 2008
```